InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Company Overview - InflaRx is a biopharmaceutical company specializing in anti-inflammatory therapeutics by targeting the complement system, particularly focusing on the C5a and C5aR pathways [2] - The company's lead product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody delivered intravenously, showing disease-modifying clinical activity and tolerability in multiple studies [2] - InflaRx is also developing INF904, an orally administered small molecule inhibitor of the C5a receptor [2] - Founded in 2007, the company has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA [2] - InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc (USA) are wholly owned subsidiaries of InflaRx NV [3] Upcoming Events - InflaRx will participate in the Guggenheim SMID Cap Biotech Conference, scheduled for February 5-6, 2025, in New York, NY [1] Contact Information - Jan Medina, CFA, serves as Vice President and Head of Investor Relations at InflaRx NV [4] - MC Services AG handles media and investor relations for InflaRx, with contacts including Katja Arnold, Laurie Doyle, and Dr Regina Lutz [4]